Genetix Biotherapeutics News and Activities

Genetix Biotherapeutics is a company listed under the stock ticker BLUE (US).

Acquisition, funding and merger involving Genetix Biotherapeutics.

• Genetix Biotherapeutics and The Carlyle Group have announced they will merge  (posted on May 26 2025)..

View the org chart displaying its 9 main executives

Most searched biographies at Genetix Biotherapeutics

• David Meek, Chief Executive Officer
• Julie Batal, Vice President, Regulatory Labeling, Advertising and ...
• Andrea Walton, Chief People Officer

Create your alert
to follow the executive moves at Genetix Biotherapeutics.

Genetix Biotherapeutics has 2,406 competitors including Eurofins (Luxembourg), Lonza (Switzerland) and BioNTech (Germany).

Popular M&A news in Biotechnology

• Laboratoire Servier has announced the acquisition of Edgewise Therapeutics  (posted on June 4 2026).
• Oak Hill Bio has just announced a $33 Million fundraising (posted on June 4 2026).
• IMU Biosciences has just announced a $53 Million fundraising (posted on June 3 2026).

Popular contacts in Biotechnology

• Jakob Uszkoreit - Co-Founder and Chief Executive Officer at Inceptive
• Jan Van de Winkel - President and Chief Executive Officer at Genmab
• Patrick Enright - Director at CuraSen Therapeutics

Learn more about the Biotechnology industry

Press releases by Genetix Biotherapeutics

• press releases | bluebird bio, Inc.
• FDA Advisory Committee Unanimously Supports beti-cel Gene Therapy for People with beta-thalassemia Who Require Regular Red Blood Cell Transfusions | bluebird bio, Inc.
• FDA Advisory Committee Unanimously Endorses eli-cel Gene Therapy for Cerebral Adrenoleukodystrophy | bluebird bio, Inc.
• bluebird bio stock trading halted today June 9th and tomorrow June 10th | bluebird bio, Inc.
• bluebird bio Announces Posting of Briefing Documents for Upcoming FDA Advisory Committee Meeting | bluebird bio, Inc.
• bluebird bio Reports First Quarter 2022 Financial Results and Highlights Operational Progress | bluebird bio, Inc.
• bluebird bio Announces European Medicines Agency’s Acceptance of Marketing Authorization Application (MAA) for elivaldogene autotemcel (eli-cel, Lenti-D™) Gene Therapy for Cerebral Adrenoleukodystrophy (CALD) - bluebird bio, Inc.
• bluebird bio to Present at Jefferies Cell Therapy Virtual Summit - bluebird bio, Inc.
• bluebird bio’s LentiGlobin™ for Sickle Cell Disease Gene Therapy (bb1111) Granted Priority Medicines (PRIME) Designation by European Medicines Agency - bluebird bio, Inc.
• U.S. Food and Drug Administration (FDA) Accepts for Priority Review Bristol Myers Squibb and bluebird bio Application for Anti-BCMA CAR T Cell Therapy Idecabtagene Vicleucel (Ide-cel, bb2121) - bluebird bio, Inc.
• View more press releases Close

Social media about Genetix Biotherapeutics

• Genetix Biotherapeutics on Wikipedia, Google News & Yahoo Finance
• Genetix Biotherapeutics on LinkedIn, X (Twitter) & YouTube